JP6306049B2 - Ａ２ａアンタゴニスト特性を有するヘテロビシクロ−置換−［１，２，４］トリアゾロ［１，５−ｃ］キナゾリン−５−アミン化合物 - Google Patents
Ａ２ａアンタゴニスト特性を有するヘテロビシクロ−置換−［１，２，４］トリアゾロ［１，５−ｃ］キナゾリン−５−アミン化合物 Download PDFInfo
- Publication number
- JP6306049B2 JP6306049B2 JP2015550682A JP2015550682A JP6306049B2 JP 6306049 B2 JP6306049 B2 JP 6306049B2 JP 2015550682 A JP2015550682 A JP 2015550682A JP 2015550682 A JP2015550682 A JP 2015550682A JP 6306049 B2 JP6306049 B2 JP 6306049B2
- Authority
- JP
- Japan
- Prior art keywords
- triazolo
- amine
- methoxy
- quinazoline
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1ccccc1 Chemical compound *c1ccccc1 0.000 description 5
- CMXSPIMOQKZJSI-UHFFFAOYSA-N CC(SC1CN(C2)S(c3ccc(C)cc3)(=O)=O)=NC12O Chemical compound CC(SC1CN(C2)S(c3ccc(C)cc3)(=O)=O)=NC12O CMXSPIMOQKZJSI-UHFFFAOYSA-N 0.000 description 1
- GZHSUXXRBWNDMF-UHFFFAOYSA-N Cc(cc1)ccc1S(N(CC1Br)CC1=O)(=O)=O Chemical compound Cc(cc1)ccc1S(N(CC1Br)CC1=O)(=O)=O GZHSUXXRBWNDMF-UHFFFAOYSA-N 0.000 description 1
- WCQBEGSIKMZWHD-UHFFFAOYSA-N Cc1cccc2c1nc(N)[n]1nc(CCN(CC3)Cc4c3cccc4)nc21 Chemical compound Cc1cccc2c1nc(N)[n]1nc(CCN(CC3)Cc4c3cccc4)nc21 WCQBEGSIKMZWHD-UHFFFAOYSA-N 0.000 description 1
- LXEXKPBPYDTHBJ-UHFFFAOYSA-N Cc1nc(CN(C2)S(c3ccc(C)cc3)(=O)=O)c2[s]1 Chemical compound Cc1nc(CN(C2)S(c3ccc(C)cc3)(=O)=O)c2[s]1 LXEXKPBPYDTHBJ-UHFFFAOYSA-N 0.000 description 1
- QBYFWIPJZYHPKM-UHFFFAOYSA-N Cc1nc(CN(CCc2n[n]3c(N)nc(c(OC)ccc4)c4c3n2)C2)c2[s]1 Chemical compound Cc1nc(CN(CCc2n[n]3c(N)nc(c(OC)ccc4)c4c3n2)C2)c2[s]1 QBYFWIPJZYHPKM-UHFFFAOYSA-N 0.000 description 1
- DQNDJDKFUJDVQW-UHFFFAOYSA-N Cc1nc(CNC2)c2[s]1 Chemical compound Cc1nc(CNC2)c2[s]1 DQNDJDKFUJDVQW-UHFFFAOYSA-N 0.000 description 1
- UTPWUHZUHWSUJG-UHFFFAOYSA-N Nc([n]1nc(CCN2Cc3ncccc3C2)nc1c1ccc2)nc1c2F Chemical compound Nc([n]1nc(CCN2Cc3ncccc3C2)nc1c1ccc2)nc1c2F UTPWUHZUHWSUJG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/087865 WO2014101120A1 (en) | 2012-12-28 | 2012-12-28 | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| CNPCT/CN2012/087865 | 2012-12-28 | ||
| PCT/CN2013/076853 WO2014101373A1 (en) | 2012-12-28 | 2013-06-06 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds for treatment of central nervous system disorder |
| CNPCT/CN2013/076853 | 2013-06-06 | ||
| PCT/US2013/076781 WO2014105666A1 (en) | 2012-12-28 | 2013-12-20 | Heterobicyclo-substituted-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504363A JP2016504363A (ja) | 2016-02-12 |
| JP2016504363A5 JP2016504363A5 (show.php) | 2017-01-12 |
| JP6306049B2 true JP6306049B2 (ja) | 2018-04-04 |
Family
ID=51019745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550682A Expired - Fee Related JP6306049B2 (ja) | 2012-12-28 | 2013-12-20 | Ａ２ａアンタゴニスト特性を有するヘテロビシクロ−置換−［１，２，４］トリアゾロ［１，５−ｃ］キナゾリン−５−アミン化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US9708347B2 (show.php) |
| EP (1) | EP2945632B1 (show.php) |
| JP (1) | JP6306049B2 (show.php) |
| KR (1) | KR102165113B1 (show.php) |
| AU (1) | AU2013370977B2 (show.php) |
| BR (1) | BR112015015468B8 (show.php) |
| CA (1) | CA2896056C (show.php) |
| CY (1) | CY1120258T1 (show.php) |
| DK (1) | DK2945632T3 (show.php) |
| ES (1) | ES2667477T3 (show.php) |
| HR (1) | HRP20180678T1 (show.php) |
| HU (1) | HUE037950T2 (show.php) |
| LT (1) | LT2945632T (show.php) |
| ME (1) | ME03034B (show.php) |
| MX (1) | MX370017B (show.php) |
| NO (1) | NO2945632T3 (show.php) |
| PL (1) | PL2945632T3 (show.php) |
| PT (1) | PT2945632T (show.php) |
| RS (1) | RS57162B1 (show.php) |
| RU (2) | RU2671628C2 (show.php) |
| SI (1) | SI2945632T1 (show.php) |
| WO (3) | WO2014101120A1 (show.php) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3253390B1 (en) * | 2015-02-06 | 2022-04-13 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| US10688082B2 (en) | 2015-06-11 | 2020-06-23 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| WO2017008205A1 (en) * | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| US10821106B2 (en) | 2015-08-21 | 2020-11-03 | Srx Cardio, Llc | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate PCSK9 protein activity |
| EP3337564A4 (en) * | 2015-08-21 | 2019-01-23 | Portola Pharmaceuticals, Inc. | COMPOSITION AND METHOD FOR THE USE OF TETRAHYDROISOCHINOLINE SMALL MOLECULES FOR THE BINDING AND MODULATION OF PCSK9 PROTEIN ACTIVITY |
| WO2017034997A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2017107087A1 (en) * | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor |
| US10329289B2 (en) | 2015-12-23 | 2019-06-25 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor |
| US20190119236A1 (en) | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| US11014904B2 (en) | 2017-01-13 | 2021-05-25 | Jiangsu Hengrui Medicine Co., Ltd. | 1,2,4-triazine-3-amine derivative, preparation method therefor, and use thereof in medicine |
| SG11201907909TA (en) | 2017-02-27 | 2019-09-27 | Betta Pharmaceuticals Co Ltd | Fgfr inhibitor and application thereof |
| UA125592C2 (uk) | 2017-03-16 | 2022-04-27 | Джянгсу Хенгруй Медісін Ко., Лтд. | ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ |
| ES2927086T3 (es) | 2017-09-28 | 2022-11-02 | Cstone Pharmaceuticals Suzhou Co Ltd | Derivado de anillo condensado como inhibidor del receptor A2A |
| EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST |
| US20210032253A1 (en) | 2018-02-06 | 2021-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof |
| EP3883576B1 (en) | 2018-11-20 | 2025-12-17 | Merck Sharp & Dohme LLC | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| MA55142A (fr) | 2018-11-20 | 2022-02-23 | Merck Sharp & Dohme | Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation |
| CA3120331A1 (en) | 2018-11-30 | 2020-06-04 | Merck Sharp & Dohme Corp. | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
| CN113329791A (zh) | 2018-11-30 | 2021-08-31 | 默沙东公司 | 作为腺苷受体拮抗剂的9-取代的氨基三唑并喹唑啉衍生物、药物组合物及其用途 |
| BR112021012685A2 (pt) | 2019-01-11 | 2021-12-28 | Omeros Corp | Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica |
| AR117844A1 (es) | 2019-01-22 | 2021-09-01 | Merck Patent Gmbh | Derivados de tiazolopiridina como antagonistas del receptor de adenosina |
| AU2019437315B2 (en) | 2019-03-26 | 2022-10-06 | Novel Pharma Inc. | Long-acting fatty acid-binding GnRH derivative and pharmaceutical composition comprising same |
| MX2022009524A (es) | 2020-02-07 | 2023-01-11 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1. |
| EP4185296A4 (en) * | 2020-07-24 | 2025-03-05 | Merck Sharp & Dohme LLC | DUAL ADENOSINE A2A RECEPTOR AND A2B RECEPTOR ANTAGONISTS FOR IMMUNO-ONCOLOGY |
| EP4185297A4 (en) * | 2020-07-24 | 2024-08-28 | Merck Sharp & Dohme LLC | Adenosine a2a and a2b receptor dual antagonists for immuno-oncology |
| CN112159411A (zh) * | 2020-10-15 | 2021-01-01 | 南京工业大学 | 一种三氟甲基取代嘧啶并[1,3]二氮杂*化合物及其制备方法 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2024169952A1 (en) | 2023-02-16 | 2024-08-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713383A (en) * | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
| EP0181282A1 (de) * | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| WO1995003806A1 (en) * | 1993-07-27 | 1995-02-09 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
| US5736564A (en) * | 1994-06-20 | 1998-04-07 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| US5571775A (en) * | 1994-07-11 | 1996-11-05 | Dowelanco | N-aryl[1,2,4]triazolo[1,5-a]pyridine-2-sulfonamide herbicides |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US5929106A (en) * | 1997-10-27 | 1999-07-27 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| WO2001092264A1 (en) | 2000-05-26 | 2001-12-06 | Schering Corporation | Adenosine a2a receptor antagonists |
| WO2001099264A1 (en) * | 2000-06-20 | 2001-12-27 | Rees, Alexander, Ellison | Electrical drive line |
| US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| EP1527074A1 (en) * | 2002-07-25 | 2005-05-04 | Pharmacia Italia S.p.A. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| TWI331036B (en) * | 2002-12-19 | 2010-10-01 | Schering Corp | Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| ATE418555T1 (de) * | 2003-04-09 | 2009-01-15 | Biogen Idec Inc | A2a-adenosinrezeptorantagonisten |
| CA2522813C (en) * | 2003-04-23 | 2009-09-08 | Schering Corporation | 2-alkynyl-and 2-alkenyl-pyrazolo-¬4,3-e|-1,2,4-triazolo-¬1,5-c|-pyrimidine adenosine a2a receptor antagonists |
| PE20070521A1 (es) * | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
| JP2010509189A (ja) | 2006-06-26 | 2010-03-25 | シェーリング コーポレイション | アデノシンＡ２ａレセプターアンタゴニスト |
| US20090062253A1 (en) | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| WO2011060207A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
-
2012
- 2012-12-28 WO PCT/CN2012/087865 patent/WO2014101120A1/en not_active Ceased
-
2013
- 2013-06-06 WO PCT/CN2013/076853 patent/WO2014101373A1/en not_active Ceased
- 2013-12-20 EP EP13866588.0A patent/EP2945632B1/en active Active
- 2013-12-20 PL PL13866588T patent/PL2945632T3/pl unknown
- 2013-12-20 US US14/655,648 patent/US9708347B2/en active Active
- 2013-12-20 BR BR112015015468A patent/BR112015015468B8/pt not_active IP Right Cessation
- 2013-12-20 RS RS20180410A patent/RS57162B1/sr unknown
- 2013-12-20 RU RU2015131148A patent/RU2671628C2/ru active
- 2013-12-20 DK DK13866588.0T patent/DK2945632T3/en active
- 2013-12-20 ME MEP-2018-97A patent/ME03034B/me unknown
- 2013-12-20 AU AU2013370977A patent/AU2013370977B2/en not_active Ceased
- 2013-12-20 KR KR1020157020147A patent/KR102165113B1/ko not_active Expired - Fee Related
- 2013-12-20 JP JP2015550682A patent/JP6306049B2/ja not_active Expired - Fee Related
- 2013-12-20 PT PT138665880T patent/PT2945632T/pt unknown
- 2013-12-20 HU HUE13866588A patent/HUE037950T2/hu unknown
- 2013-12-20 SI SI201330980T patent/SI2945632T1/en unknown
- 2013-12-20 LT LTEP13866588.0T patent/LT2945632T/lt unknown
- 2013-12-20 HR HRP20180678TT patent/HRP20180678T1/hr unknown
- 2013-12-20 RU RU2018136104A patent/RU2018136104A/ru unknown
- 2013-12-20 CA CA2896056A patent/CA2896056C/en active Active
- 2013-12-20 MX MX2015008481A patent/MX370017B/es active IP Right Grant
- 2013-12-20 WO PCT/US2013/076781 patent/WO2014105666A1/en not_active Ceased
- 2013-12-20 NO NO13866588A patent/NO2945632T3/no unknown
- 2013-12-20 ES ES13866588.0T patent/ES2667477T3/es active Active
-
2017
- 2017-02-02 US US15/423,238 patent/US10011615B2/en active Active
-
2018
- 2018-05-04 CY CY20181100472T patent/CY1120258T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6306049B2 (ja) | Ａ２ａアンタゴニスト特性を有するヘテロビシクロ−置換−［１，２，４］トリアゾロ［１，５−ｃ］キナゾリン−５−アミン化合物 | |
| EP1416935B1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| EP3038466B1 (en) | 2,2-difluorodioxolo a2a receptor antagonists | |
| TWI485151B (zh) | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 | |
| KR20140059195A (ko) | 트리시클릭 헤테로시클릭 화합물 및 jak 저해제 | |
| JP5992096B2 (ja) | Ｐｄｅ１０阻害剤としてのトリアゾロ化合物 | |
| EA035929B1 (ru) | ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ | |
| EP1567527A1 (en) | Condensed pyrazolo derivatives | |
| AU2002324029A1 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| WO2011035518A1 (zh) | 嘧啶衍生物和类似物及其制备方法和用途 | |
| JP2022502424A (ja) | モノアシルグリセロールリパーゼ調節因子 | |
| CN108699065B (zh) | 作为激酶抑制剂的三环类化合物和组合物 | |
| EP3313852B1 (en) | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors | |
| CN105025899B (zh) | 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物 | |
| US20250114345A1 (en) | Compounds and compositions as cbp/p300 degraders and uses thereof | |
| WO2011064211A1 (en) | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls | |
| WO2015113980A1 (en) | (hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders | |
| HK1065483B (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161124 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171019 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171218 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6306049 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |